Literature DB >> 11746500

Modulation of human cytomegalovirus immediate-early gene enhancer by mitogen-activated protein kinase kinase kinase-1.

B Sun1, G Harrowe, C Reinhard, C Yoshihara, K Chu, S Zhuo.   

Abstract

The immediate-early (IE) promoter of human cytomegalovirus (HCMV) constitutes a primary genetic switch, which determines the progression of viral infection. Earlier reports by others have shown mitogen-activated protein kinase kinase kinase-1 (MEKK1) to be able to up-regulate HCMV-IE promoter through downstream mitogen-activated protein kinase (MAPK) pathways. However, we noticed that the activation of the HCMV-IE promoter by constitutively active MEKK1 (MEKK1-TRU) might not be through the MAPK pathways. Using a HCMV-IE enhancer/promoter (- 522 to + 72) driving a luciferase reporter, we demonstrated that the downstream MAPK activation actually repressed the up-regulation of the promoter by MEKK1 in CHO-K1 and human 293 cells. We further found that the up-regulation of HCMV-IE promoter by MEKK1 could be in great extent suppressed by over-expression of IkappaBalpha. Deletion of the NFkappaB/rel sites in the HCMV-IE enhancer region by mutagenesis proportionally reduced the transcriptional activation by MEKK1-TRU, whereas deletion of the ATF/CREB binding sites or cyclic AMP response elements (CRE) had no effects. Furthermore, the NFkappaB/rel deletion mutant also showed repression on the basic transcription activity of the HCMV-IE promoter. Our results indicate that the NFkappaB/rel sites are not only responsible for the modulation of HCMV-IE enhancer activity by MEKK1 but also control the basic transcription activity of the HCMV-IE promoter. On the other hand, the four consensus CRE sites were found to have no function in the activation of the promoter by MEKK1. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11746500     DOI: 10.1002/jcb.1251

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  7 in total

1.  Interactions between the cytomegalovirus promoter and the estrogen response element: implications for design of estrogen-responsive reporter plasmids.

Authors:  K Derecka; C K Wang; A P F Flint
Journal:  J Biomol Tech       Date:  2006-07

2.  Human kinome profiling identifies a requirement for AMP-activated protein kinase during human cytomegalovirus infection.

Authors:  Laura J Terry; Livia Vastag; Joshua D Rabinowitz; Thomas Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-06       Impact factor: 11.205

3.  Cytomegalovirus promoter up-regulation is the major cause of increased protein levels of unstable reporter proteins after treatment of living cells with proteasome inhibitors.

Authors:  Beatriz Alvarez-Castelao; Idoia Martín-Guerrero; Africa García-Orad; José G Castaño
Journal:  J Biol Chem       Date:  2009-08-13       Impact factor: 5.157

4.  Human cytomegalovirus pUL97 kinase induces global changes in the infected cell phosphoproteome.

Authors:  Adam Oberstein; David H Perlman; Thomas Shenk; Laura J Terry
Journal:  Proteomics       Date:  2015-05-12       Impact factor: 3.984

5.  Heat shock enhances CMV-IE promoter-driven metabotropic glutamate receptor expression and toxicity in transfected cells.

Authors:  Sergey Pshenichkin; Alexander Surin; Elena Surina; Małgorzata Klauzińska; Ewa Grajkowska; Victoria Luchenko; Monika Dolińska; Barbara Wroblewska; Jarda T Wroblewski
Journal:  Neuropharmacology       Date:  2011-01-15       Impact factor: 5.250

6.  Analysis of signal transduction pathways in macrophages using expression vectors with CMV promoters: a cautionary tale.

Authors:  Madhuri Ramanathan; György Haskó; Samuel Joseph Leibovich
Journal:  Inflammation       Date:  2005-04       Impact factor: 4.092

7.  Neutrality of the canonical NF-kappaB-dependent pathway for human and murine cytomegalovirus transcription and replication in vitro.

Authors:  Chris A Benedict; Ana Angulo; Ginelle Patterson; Sukwon Ha; Huang Huang; Martin Messerle; Carl F Ware; Peter Ghazal
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.